Aims To study the risk factors associated with blindness after treatment of acute primary angle closure (APAC), and to identify the critical time window to decrease rate of blindness.
Methods In this multicentre retrospective case series, 1030 consecutive subjects (1164 eyes) with APAC in China were recruited. The rates of blindness were analysed up to 3 months after treatment of APAC. A logistic regression was used to identify the risk factors associated with blindness, including age, gender, distance to hospital, rural or urban settings, treatment method, education level, time from symptom to treatment (TST, hours) and presenting intraocular pressure (IOP). The critical time window associated with a blindness rate of ≤1% was calculated based on a cubic function by fitting TST to the rate of blindness at each time point.
Results The rate of blindness after APAC was 12.54% after treatment. In multivariate regression, education level, TST and presenting IOP were risk factors for blindness (p=0.022, 0.004 and 0.001, respectively). The critical time window associated with a blindness rate of ≤1% was 4.6 hours.
Conclusions and relevance Education level, TST and presenting IOP were risk factors for blindness after APAC. Timely medical treatment is key in reducing blindness after APAC.
Statistics from Altmetric.com
Presented at American Glaucoma Society Annual Meeting, 2019 World Glaucoma Congress Meeting, 2019.
Contributors SL: investigation design, conduct, interpretation and manuscript preparation, critical revision of the article. GT: data collection. SF: data collection. GZ: data collection. JL: data collection. HZ: data collection. JJ: data collection. WL: data collection. AL: data collection. NW: data collection. DM: data collection. XP: data collection. HF: data collection. KC: data analysis and manuscript preparation. JZ: manuscript preparation. VV: manuscript preparation. YCH: manuscript preparation and critical revision of the article. YH: data interpretation, manuscript preparation and critical revision of the article.
Funding The Capital Health Research and Development of Special (No. 2016-2-1081).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study protocol received approval from the institutional review board and ethics committee of each centre. This study complied with the Health Insurance Portability and Accountability Act regulations and adhered to the tenets of the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request. Data could be available from the corresponding author by reasonable inquire.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.